Study ID: NHL-TL011-102

Study Title

A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

Teva Identifier

NHL-TL011-102

ClinicalTrials.gov Identifier

NCT01205737

Study Status

Completed

Trial Condition(s)

DLBCL

Interventions

Biological: TL011 | Biological: Rituximab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
cancer icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 80 Years

Trial Duration

09/01/2010 - 09/01/2013

Phase

Phase 1

Study Type

Interventional